# AstraZeneca updates on DARE-19 Phase III trial

- Link: https://www.directorstalkinterviews.com/astrazeneca-updates-on-dare-19-phase-iii-trial/412976224
- Published: 2021-04-12T07:14:28+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Saint Luke’s Mid America Heart Institute today announced high-level results 
of the primary analysis from the DARE-19 Phase III trial assessing the potential
of _Farxiga_ (dapagliflozin) to treat patients hospitalised with COVID-19 who are
at risk of developing serious complications.

The trial did not achieve statistical significance for the primary endpoint of prevention
measuring organ dysfunction and all-cause mortality, and the primary endpoint of
recovery measuring a change in clinical status (from early recovery to death), at
30 days.

DARE-19 was the first Phase III trial to evaluate the safety and efficacy of a sodium-
glucose co-transporter-2 (SGLT2) inhibitor in patients hospitalised with COVID-19
who also have risk factors for developing serious complications, including hypertension(
HTN), type-2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), heart
failure (HF) or chronic kidney disease (CKD) Stages 3-4.^(1,2) Cardiac, renal and
metabolic comorbidities have been associated with poor outcomes and death in patients
hospitalised with COVID-19.^(3,4)

> **Mikhail N. Kosiborod, M**.**D., cardiologist at Saint Luke’s Mid America Heart
> Institute, Vice President of Research at Saint Luke’s Health System, and principal
> investigator of DARE-19, said: **“DARE-19 provided important data on the potential
> benefits and risks of using SGLT2 inhibitors to treat hospitalised patients with
> COVID-19. While the trial did not achieve statistical significance, the findings
> are very interesting and valuable, and will inform future clinical science. Also,
> of importance, we learned that dapagliflozin’s well-established safety profile
> was consistent in DARE-19.”

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said**: “Prior
> to the DARE-19 Phase III trial, there was little data on the use of SGLT2 inhibitors
> in hospitalised patients with COVID-19 and we have now helped to fill this knowledge
> gap. We look forward to the efficacy and safety data being presented in the coming
> weeks.”

The safety and tolerability profile for _Farxiga_ at 30 days in the trial was consistent
with the well-established safety profile of the medicine.

The full DARE-19 trial results will be presented at the American College of Cardiology
Scientific Sessions in May 2021.

**DARE-19**

DARE-19 was an international, randomised, double-blind, placebo-controlled, investigator-
sponsored Phase III trial in 1,250 patients evaluating the efficacy and safety of
_Farxiga_ in addition to background local standard of care therapy in adults who
are hospitalised with COVID-19 at the time of trial enrolment. Patients enrolled
in DARE-19 also had a medical history of HTN, ASCVD, heart failure, T2D or CKD Stages
3-4 and received _Farxiga_ or placebo for 30 days.^(1,2)

**Farxiga**

_Farxiga_ (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor.
The research for _Farxiga_ is advancing from cardiorenal effects to prevention and
organ protection as science continues to identify the underlying links between the
heart, kidneys and pancreas. Damage to one of these organs can cause the other organs
to fail – contributing to leading causes of death worldwide, including T2D, HF and
CKD.

For nearly a decade _Farxiga_ has been an effective monotherapy and part of combination
therapy as an adjunct to diet and exercise to improve glycaemic control in adults
with T2D. Following results from the landmark DECLARE-TIMI 58 Phase III cardiovascular(
CV) outcomes trial,^(5) it is approved in adults with T2D to reduce the risk of 
hospitalisation for heart failure or CV death when added to standard of care. _Farxiga_
is also the first SGLT2 inhibitor approved for the treatment of HFrEF in adults 
with and without T2D.

In August 2020, results from the DAPA-CKD Phase III trial demonstrated that _Farxiga_
achieved unprecedented reduction in the composite risk of kidney failure and CV 
or renal death in patients with CKD with and without T2D versus placebo.^(6) It 
is now the first SGLT2 inhibitor shown to significantly improve overall survival
in a renal outcomes trial for this patient population and provide organ protection.
_Farxiga_ is not yet approved for the treatment of CKD.

DapaCare is a robust programme of clinical trials to evaluate the potential CV, 
renal and organ protection benefits of _Farxiga_. It includes more than 35 completed
and ongoing Phase IIb/III trials in more than 35,000 patients, as well as more than
2.5 million patient-years’ experience. It is currently being assessed in patients
with HFpEF in the DELIVER Phase III trial. _Farxiga_ is also being tested in patients
without T2D following an acute myocardial infarction (MI) or heart attack in the
DAPA-MI Phase III trial – a first of its kind, indication-seeking registry-based
randomised controlled trial.

**AstraZeneca in CVRM**

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s 
three therapy areas and is a key growth driver for the Company. By following the
science to understand more clearly the underlying links between the heart, kidneys
and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection
and improve outcomes by slowing disease progression, reducing risks and tackling
co-morbidities. The Company’s ambition is to modify or halt the natural course of
CVRM diseases and potentially regenerate organs and restore function, by continuing
to deliver transformative science that improves treatment practices and cardiovascular
health for millions of patients worldwide.

Share on:
